Limits...
Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies.

Schmitt M, Magdolen V, Yang F, Kiechle M, Bayani J, Yousef GM, Scorilas A, Diamandis EP, Dorn J - Radiol Oncol (2013)

Bottom Line: In contrast, for breast cancer, a series of KLKs was found to be downregulated.However, in breast cancer, KLK4 is elevated which is also true for ovarian and prostate cancer.In such cases, selective synthetic KLK inhibitors that aim at blocking the proteolytic activities of certain KLKs may serve as future candidate therapeutic drugs to interfere with tumor progression and metastasis.

View Article: PubMed Central - PubMed

Affiliation: Clinical Research Unit, Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

ABSTRACT

Background: Tumor tissue-associated KLKs (kallikrein-related peptidases) are clinically important biomarkers that may allow prognosis of the cancer disease and/or prediction of response/failure of cancer patients to cancer-directed drugs. Regarding the female/male reproductive tract, remarkably, all of the fifteen KLKs are expressed in the normal prostate, breast, cervix uteri, and the testis, whereas the uterus/endometrium and the ovary are expressing a limited number of KLKs only.

Conclusions: Most of the information regarding elevated expression of KLKs in tumor-affected organs is available for ovarian cancer; depicting them as valuable biomarkers in the cancerous phenotype. In contrast, for breast cancer, a series of KLKs was found to be downregulated. However, in breast cancer, KLK4 is elevated which is also true for ovarian and prostate cancer. In such cases, selective synthetic KLK inhibitors that aim at blocking the proteolytic activities of certain KLKs may serve as future candidate therapeutic drugs to interfere with tumor progression and metastasis.

No MeSH data available.


Related in: MedlinePlus

Comparative mRNA and protein expression in normal tissues of the reproductive tract
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3814276&req=5

f1-rado-47-04-319: Comparative mRNA and protein expression in normal tissues of the reproductive tract

Mentions: In this respect, in the last decade, mRNA and protein expression of various members of the KLK family has been studied extensively in a variety of normal and diseased human tissues, including the ovary and ovarian cancer 5,9,23 In normal human ovary tissues, KLK expression at the mRNA level is highest for KLK6–8 and 10, whereas low to moderate expression was noted for KLK1, 9, 11, 13 and 14 with no expression for KLK2–5, 12, and 15. (Table 1, Figure 1). At the protein level, low to moderate amounts were found for KLK1, 5–8, and 10–14; KLK2–4, 9 and 15 proteins are not expressed (Table 1, Figure 1).23 Compared to normal ovarian tissues, concomitant up regulation of twelve (KLK3–11 and 13–15) of the fifteen KLKs at the mRNA and/or protein expression level is characteristic for ovarian cancer (Table 1, Figure 2).24–40 Regarding the clinical impact of some of the KLKs, expression of KLK4–7, 10 and 15 indicates poor prognosis; KLK8, 9, 11, 13 and 14 are markers of a favorable prognosis. Furthermore, KLK5–8, 10, 11 and 13 are judged as promising predictive ovarian cancer biomarkers.


Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies.

Schmitt M, Magdolen V, Yang F, Kiechle M, Bayani J, Yousef GM, Scorilas A, Diamandis EP, Dorn J - Radiol Oncol (2013)

Comparative mRNA and protein expression in normal tissues of the reproductive tract
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3814276&req=5

f1-rado-47-04-319: Comparative mRNA and protein expression in normal tissues of the reproductive tract
Mentions: In this respect, in the last decade, mRNA and protein expression of various members of the KLK family has been studied extensively in a variety of normal and diseased human tissues, including the ovary and ovarian cancer 5,9,23 In normal human ovary tissues, KLK expression at the mRNA level is highest for KLK6–8 and 10, whereas low to moderate expression was noted for KLK1, 9, 11, 13 and 14 with no expression for KLK2–5, 12, and 15. (Table 1, Figure 1). At the protein level, low to moderate amounts were found for KLK1, 5–8, and 10–14; KLK2–4, 9 and 15 proteins are not expressed (Table 1, Figure 1).23 Compared to normal ovarian tissues, concomitant up regulation of twelve (KLK3–11 and 13–15) of the fifteen KLKs at the mRNA and/or protein expression level is characteristic for ovarian cancer (Table 1, Figure 2).24–40 Regarding the clinical impact of some of the KLKs, expression of KLK4–7, 10 and 15 indicates poor prognosis; KLK8, 9, 11, 13 and 14 are markers of a favorable prognosis. Furthermore, KLK5–8, 10, 11 and 13 are judged as promising predictive ovarian cancer biomarkers.

Bottom Line: In contrast, for breast cancer, a series of KLKs was found to be downregulated.However, in breast cancer, KLK4 is elevated which is also true for ovarian and prostate cancer.In such cases, selective synthetic KLK inhibitors that aim at blocking the proteolytic activities of certain KLKs may serve as future candidate therapeutic drugs to interfere with tumor progression and metastasis.

View Article: PubMed Central - PubMed

Affiliation: Clinical Research Unit, Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

ABSTRACT

Background: Tumor tissue-associated KLKs (kallikrein-related peptidases) are clinically important biomarkers that may allow prognosis of the cancer disease and/or prediction of response/failure of cancer patients to cancer-directed drugs. Regarding the female/male reproductive tract, remarkably, all of the fifteen KLKs are expressed in the normal prostate, breast, cervix uteri, and the testis, whereas the uterus/endometrium and the ovary are expressing a limited number of KLKs only.

Conclusions: Most of the information regarding elevated expression of KLKs in tumor-affected organs is available for ovarian cancer; depicting them as valuable biomarkers in the cancerous phenotype. In contrast, for breast cancer, a series of KLKs was found to be downregulated. However, in breast cancer, KLK4 is elevated which is also true for ovarian and prostate cancer. In such cases, selective synthetic KLK inhibitors that aim at blocking the proteolytic activities of certain KLKs may serve as future candidate therapeutic drugs to interfere with tumor progression and metastasis.

No MeSH data available.


Related in: MedlinePlus